Testing glutathione with immunotherapy and chemo for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a supplement called glutathione to the usual immunotherapy (anti-PD-1) plus chemotherapy for advanced non-small cell lung cancer that has stopped responding to first treatment. It aims to see if this combination works better at shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of lung cancer — either squamous cell or adenocarcinoma.
- Your cancer has gotten worse after your first round of treatment (chemotherapy or chemo-immunotherapy).
- You are 18 years old or older.
- You are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.